Table 2 Number of Participants with Treatment Emergent Adverse Eventsa leading to Study Drug Withdrawal (Safety Population, N = 335)
Adverse Event Preferred Termb | M207 3.8 mg n (%) |
|---|---|
Amenorrhoeac | 1 (0.3) |
Anxietyc | 2 (0.6) |
Application site haemorrhage | 1 (0.3) |
Application site pain | 1 (0.3) |
Application site swelling | 1 (0.3) |
Application site pain, erythema, haemorrhage, and swelling | 1 (0.3) |
Breast cancer stage IIc | 1 (0.3) |
Dysphagia | 1 (0.3) |
Facial Pain | 1 (0.3) |
Hangover | 1 (0.3) |
Migraine | 1 (0.3) |
Nausea | 1 (0.3) |
Paraesthesia and somnolence | 1 (0.3) |
Pharyngeal oedema | 1 (0.3) |